Shop to Save Lives: Susan G. Komen® Launches 2024 “Live Pink” Program Showcasing Partners Supporting Those Impacted by Breast Cancer
The Annual ‘Live Pink’ Program Turns Everyday Purchases into Lifesaving Support for Breast Cancer During October’s National Awareness Month DALLAS–(BUSINESS... Read more.
Platform Science to Acquire Trimble’s Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology
Partnership will Accelerate Global Expansion of Virtual Vehicle Trimble to Become a Shareholder in Platform Science’s Expanded Business WESTMINSTER, Colo. &... Read more.
Doğuş Technology and Doğuş Construction Participate in ConteQ Expo 2024 with Innovative Projects
DOHA, Qatar–(BUSINESS WIRE)–Doğuş Technology, one of Turkey’s leading tech companies, will showcase its innovative, technology-driven solutions... Read more.
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera’s Ability to Predict Overall Survival
Shows nearly 10x advantage in overall survival at 36 months based on ctDNA status and affirms Signatera’s ability to predict chemotherapy benefit Shows a 50% reduction... Read more.
Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers
Comprehensive Platform Combines Masimo’s Industry-leading Biosensing Capabilities with Snapdragon Wearable Platforms to Expand the Wear OS by Google™ Ecosystem... Read more.
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented... Read more.
Dongfeng Embarks on a New Journey in Europe, Various New Products Debuted Offer Diversified Mobility Options
TURIN, Italy–(BUSINESS WIRE)–On September 12th, Dongfeng Motor held the DONGFENG DAYS · EUROPE launch event in Turin, Italy, officially announcing the... Read more.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking... Read more.
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
KEYNOTE-A18 is the first Phase 3 study of an immunotherapy in combination with CRT to demonstrate a statistically significant and clinically meaningful improvement... Read more.
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
– Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients... Read more.